News

In the BREATHER study young people with HIV infection on stable efavirenz based therapy in combination with two nucleoside inhibitors (NRTI) were included in a study comparing continued daily therapy to treatment 5 days a week. 199 HIV positive patients aged 8-24...

Data from 3 French prospective multicenter cohorts including more than 6,000 patients treated with DAA were analyzed for reoccurrence of HCC during or after treatment. In the “HEPATHER” cohort 267 patients with a history of treated HCC were found. 189 had been...

In a retrospective Italian study 344 consecutive cirrhotic patients treated with direct-acting antivirals (DAA) were evaluated for the occurrence of HCC within the first 24 weeks after therapy. Sustained viral response was achieved in 91 %. 39 patients were...

HIV positive patients from 12 large HIV reference centers in France who started HIV therapy with either abacavir with lamivudine (ABC/3TC) or tenofovir with emtricitabine (TDF/FTC) from 2004 until June 2013 were identified and included in the comparison between the...

Serum samples from an open label treatment study of hepatitis C with ledipasvir/sofosbuvir in Taiwan and Korea were retrospectively analyzed for hepatitis B core antibodies (HBcAb). Positive HBsAg was an exclusion criterion and all patients participating in the...

In a safety communication from The U.S. Food and Drug Administration (FDA) a warning about the risk of hepatitis B (HBV) reactivation in patients who are treated for hepatitis C (HCV) with direct-acting antiviral (DAA) medicines was issued. FDA identified 24 cases...

Patients with chronic hepatitis B were randomized 2:1 to treatment with tenofovir disoproxil fumarate (TDF) or adefovir for 48 weeks in two separate studies. In the first study Hepatits B e-antigen (HBeAg) negative patients were included and in the second study the...

In a national cohort study in Taiwan treatment naïve patients with hepatitis B and cirrhosis who received entecavir treatment were evaluated both prospectively and retrospectively and were compared to historical untreated controls. Besides having hepatitis B and...

Patients with chronic hepatitis B with HBV-DNA > 103 IU/mL and proven resistance to LAM were randomised to treatment with either TDF monotherapy or the combination of TDF and LAM. LAM resistance was defined as the presence of the M204V/I mutation with or without...

TAF has been approved for HIV therapy and has been associated with less nephrotoxicity and less bone loss than tenofovir disoproxil fumarate (TDF). TAF is not yet approved for hepatitis B therapy. 51 non-cirrhotic, treatment naive subjects with chronic hepatitis B...

Pages